742-P: Antidrug Antibodies Do Not Impact Pharmacokinetics, Efficacy, and Safety of Tirzepatide: Analysis of Data from 7 Phase 3 Studies

• Published in: Diabetes (New York, N.Y.) Vol. 71; no. Supplement_1
• Main Authors: CALDERON, BORIS, MULLINS, GARRETT R., HODSDON, MICHAEL, LI, GRACE, ANGLIN, GREG, URVA, SHWETA, SCHNECK, KAREN, BARDOS, JENNIFER N., MARTINS, RICARDO F., BROWN, KATELYN
• Format: Journal Article
• Language: English
• Published: New York American Diabetes Association 01.06.2022
• Subjects: Amino acids; Antibodies; Antidiabetics; Clinical trials; Diabetes; Diabetes mellitus (non-insulin dependent); GIP protein; GLP-1 receptor agonists; Glucagon; Hypersensitivity; Immune response; Immunogenicity; Patients; Peptides; Pharmacokinetics; Safety; Japan

Tirzepatide (TZP) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide (GLP) -1 receptor agonist developed for the treatment of type 2 diabetes. Patients receiving TZP may develop an immune response to the 39 amino acid synthetic peptide. This study aimed to evaluat...